Oncology
CAR-TCR 2023 – Josh Ludwig

CAR-TCR 2023 – Josh Ludwig

Innovation was the watchword at CAR-TCR in Boston last month, but one of the limitations of innovation is that it can be challenging for an industry to transition from the rapid iteration s

Oncology
CAR-TCR 2023 – Becky Cap

CAR-TCR 2023 – Becky Cap

In an industry growing as quickly as cell therapy, keeping up with the demands of manufacturing and treatment is a challenge for the whole industry to tackle together, including stakeholder

Oncology
CAR-TCR 2023 – Jason Noon

CAR-TCR 2023 – Jason Noon

If we learned anything at CAR-TCR it’s that CAR-T therapies are still a relatively new treatment modality and innovation is happening along many different axes.

Sales & Marketing

Sales & Marketing
Interview with Craig Ackerman Reuters at Pharma USA 2026

Biotech is back, with Craig Ackerman

In Philadelphia last month, pharmaphorum spoke with Craig Ackerman, a partner at the Alexander Group, about launches, AI best practices, and more.

Digital

Market Access

Editor's Picks

  1. GBL joins CVC in €10.7bn takeover bid for Recordati
  2. After refusing to resign, CDER head Høeg is fired
  3. As Ebola deaths climb, search begins for vaccine
  4. NICE changes stance on Genmab's cervical cancer drug
  5. Remepy's hybrid Parkinson's therapy poised for phase 3

Newsletters and Deep Dive
digital magazine

Oncology

more

Patients

more

R&D

more